Characterization and impact of response to holding/bridging therapy in second-line large Bcell lymphoma patients treated with axicabtagene ciloleucel: a LYSA study from the French DESCAR-T registry
The optimal approach for holding or bridging therapy (H/BT) prior to second line axicabtagene ciloleucel (axi-cel) remains undefined, and the prognostic impact of response to H/BT remains debated. Here, we characterize real-world H/BT strategies and evaluate the impact of response on outcome following axi-cel infusion in the second-line setting for relapse or refractory (R/R) large B-cell lymphoma (LBCL). We included all adults with R/R LBCL within 12 months of first-line therapy who received axi-cel in the nationwide French DESCAR-T cohort (NCT04328298). The primary objective was to EFS between H/BT responders and nonresponders, as per Lugano criteria, using propensity score matching (PSM). Secondary objectives were to characterize H/BT modalities, corresponding responses, and to identify predictors of EFS at infusion. Among 566 patients included, 469 (83%) received chemotherapy-based H/BT, while 97 (17%) received a chemo-free approach, including no H/BT. Patients treated with chemotherapy-based H/BT had more advanced disease characteristics and exhibited inferior EFS compared to those receiving chemo-free approaches. After PSM, OS was significantly improved in responders versus non-responders (HR=0·70 [95% CI 0·51-0·96], p=0·0292), while the EFS benefit no longer reached statistical significance (HR=0·86 [95%CI 0·70-1·07], p=0·1739). Given that only patients ultimately receiving axi-cel were analyzed, the impact of H/BT response may have been underestimated. A predictive score combining response to H/BT, international prognostic index, LDH, and CRP at infusion identified two risk groups with significantly different EFS. In conclusion, H/BT response appears to be associated with axi-cel outcomes particularly when combined to inflammatory markers and residual LDH.
Authors
- Elodie Gat
- Blandine Guffroy
- Aline Schmidt (ORCID: https://orcid.org/0000-0003-0278-7479)
- Michael L. Loschi (ORCID: https://orcid.org/0000-0002-4460-5939)
- Sylvain Choquet (ORCID: https://orcid.org/0000-0002-7791-0470)
- Pierre Bories (ORCID: https://orcid.org/0000-0002-2252-0395)
- Gabriel Brisou (ORCID: https://orcid.org/0000-0003-0771-683X)
- Adrien Chauchet (ORCID: https://orcid.org/0000-0003-3665-6805)
- Roch Houot (ORCID: https://orcid.org/0000-0003-1729-8213)
- Antoine Capes (ORCID: https://orcid.org/0000-0002-5086-9519)
- Guillaume Cartron (ORCID: https://orcid.org/0000-0003-0659-9635)
- Catherine Thiéblemont (ORCID: https://orcid.org/0000-0002-9941-2448)
- Amandine Durand (ORCID: https://orcid.org/0000-0002-4354-365X)
- Stéphanie Guidez (ORCID: https://orcid.org/0000-0001-8755-5591)
- Laure L Lebras (ORCID: https://orcid.org/0009-0007-3267-3882)
- Franck Morschhauser (ORCID: https://orcid.org/0000-0002-3714-9824)
- Emmanuel Bachy (ORCID: https://orcid.org/0000-0003-2694-7510)
- Florent Malard (ORCID: https://orcid.org/0000-0002-3474-0002)
- Guillaume Manson (ORCID: https://orcid.org/0000-0003-4280-7825)
- Estelle Bourbon (ORCID: https://orcid.org/0000-0001-6724-6863)
- Gandhi Laurent Damaj (ORCID: https://orcid.org/0000-0002-4689-3882)
- Olivier Hermine (ORCID: https://orcid.org/0000-0003-2574-3874)
- Sylvain Carras (ORCID: https://orcid.org/0000-0002-0796-7914)
- Rémy Duléry (ORCID: https://orcid.org/0000-0002-5024-1713)
- Laura Herbreteau
- Benoît Tessoulin (ORCID: https://orcid.org/0000-0001-7600-3329)
- Fabien Le Bras (ORCID: https://orcid.org/0000-0003-1424-2716)
- Fabrice Jardin (ORCID: https://orcid.org/0000-0002-6804-7943)
- Justine Decroocq (ORCID: https://orcid.org/0000-0002-9924-2979)
- Caroline Rossoni (ORCID: https://orcid.org/0000-0002-0097-8135)
- François‐Xavier Gros (ORCID: https://orcid.org/0000-0001-8998-3039)
- Jacques‐Olivier Bay (ORCID: https://orcid.org/0000-0002-7032-5180)
- Cristina Castilla Llorente
- Marie‐Thérèse Rubio (ORCID: https://orcid.org/0000-0003-3732-5442)
- Julie Abraham (ORCID: https://orcid.org/0009-0008-5593-7761)
- Jean‐Valère Malfuson
- Ludovic Fouillet (ORCID: https://orcid.org/0009-0007-3281-5043)
- Laurianne Drieu La Rochelle
- Magalie Joris
- Steven Le Gouill
Institutions
- Hôpital Necker-Enfants Malades (FR)
- Université Paris-Est Créteil (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Cochin (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Saint-Antoine (FR)
- Centre Léon Bérard (FR)
- The Lymphoma Academic Research Organisation (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Limoges (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Hôpital d'instruction des Armées Percy (FR)
- Hôpital Universitaire Dupuytren (FR)
- Hôpital Saint-Louis (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- Institut Paoli-Calmettes (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Centre Henri Becquerel (FR)
- Institut Curie (FR)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- Haematologica
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3324/haematol.2026.301559
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00